omniture
logo
Search
信达生物制药（苏州）有限公司 Innovent BiologicsInc
Media Room

Photo News

rss
Innovent Announces 2025 Interim Results and Business Updates

Innovent Announces 2025 Interim Results and Business Updates

2025-08-27 18:08 2856
Innovent Biologics Showcases

Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms

2025-06-30 12:04 2334
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management

Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management

2025-06-27 17:49 2749
Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions

Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions

2025-06-24 22:02 2542
Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation

Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation

2025-05-19 08:00 3438
Innovent Announces 2024 Annual Results and Business Updates

Innovent Announces 2024 Annual Results and Business Updates

2025-03-26 19:02 4257
Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

2025-01-17 07:00 4541
Innovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine Pipeline

Innovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine Pipeline

2024-06-28 08:00 3702
Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024

Innovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024

2024-06-25 08:00 3612
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity

Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity

2024-01-02 08:00 10618
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension

Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension

2023-12-27 08:00 4648
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

2023-12-18 08:00 7457
Innovent's MSCI ESG Rating Upgraded to A

Innovent's MSCI ESG Rating Upgraded to A

2023-11-30 21:37 8126
Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director

Innovent Appoints Mr. Gary Zieziula as Independent Non-executive Director

2022-06-01 08:00 3730
Significant Weight Loss and Multiple Metabolic Benefits: Phase 1b Study Results of IBI362 in Chinese Participants with Overweight or Obesity Published in EClinicalMedicine by the Lancet

Significant Weight Loss and Multiple Metabolic Benefits: Phase 1b Study Results of IBI362 in Chinese Participants with Overweight or Obesity Published in EClinicalMedicine by the Lancet

2021-08-18 08:00 4491
Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology

Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology

2021-06-21 08:00 8029